doi:10.1002/ejhf.1356 Online publish-ahead-of-print 6 December 2018 Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation Atrial fibrillation is common among patients with advanced heart failure who are listed for transplantation. 1 The choice of anticoagulation in these patients can be challenging. Compared with vitamin K antagonists (VKAs), non-vitamin K oral anticoagulants (NOACs) offer a similar efficacy, less bleeding complications, a better pharmacokinetic predictability and greater patient comfort. 2 NOACs have a shorter half-life, leading to a quick normalization of haemostasis after the last intake. This feature has greatly simplified the management of elective procedures in patients on NOACs. However, in case of urgent non-deferrable surgery -such as heart transplantation -an immediate normalization of the coagulation system is required. Idarucizumab is a monoclonal antibody fragment that was developed to neutralize the activity of the direct thrombin inhibitor dabigatran. Idarucizumab has recently been approved by the European Medicines Agency and the Food and Drug Administration (FDA) for emergency surgery or in case of life-threatening bleeding in patients taking dabigatran, based on the results of the RE-VERSE AD study. 3 In RE-VERSE AD, a single dose of 5 g of idarucizumab led to an immediate, complete and sustained reversal of the anticoagulant effect of dabigatran. Although RE-VERSE AD included 202 patients requiring emergent procedures, there have been only two reports of idarucizumab use in heart transplant surgery to date. 4, 5 Here we describe our experience of dabigatran reversal with idarucizumab in 10 patients undergoing heart transplant surgery at the University Hospitals Leuven.
At the time of listing for heart transplantation, patients requiring anticoagulation because of non-valvular atrial fibrillation, CHA 2 DS 2 -VASc score ≥ 2 and without ventricular assist device (VAD) or end-stage renal failure precluding the use of NOAC, were started on or switched to dabigatran. Upon availability of a donor organ, dabigatran was neutralized with 5 g of intravenous idarucizumab, administered as two 50 mL bolus infusions, each containing 2.5 g of idarucizumab, no more than 15 min apart, immediately prior to induction of anaesthesia. None of the patients had previously been exposed to idarucizumab. Patients were not screened for pre-existing anti-idarucizumab antibodies. 3 Ten patients have received a heart transplant using this protocol since its implementation at our centre on 1 October 2015. Patient characteristics are summarized in Table 1 . Mean age was 57.9 years, 9 of the 10 patients were male, median CHA 2 DS 2 -VASc score was 3 and mean estimated glomerular filtration rate at time of transplantation was 53 mL/min. All patients underwent primary sternal closure. Seven of the 10 patients were taking dabigatran 150 mg bid, three patients 110 mg bid. Mean time since last intake was 6.2 h. One patient (patient 6) took antiplatelet therapy in addition to dabigatran. Evolution of dabigatran concentration (measured by a calibrated diluted thrombin time assay 6 ) and activated partial thromboplastin time 
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Research letters Later aPTT values were affected by the administration of heparin to achieve full anticoagulation for cardiopulmonary bypass. During surgery, patients received on average 1.0 unit of packed cell transfusion, 4.1 units fresh frozen plasma, 0.9 pools platelets and 587 mL blood that was recovered via cell salvage. Two patients (20%) needed re-intervention because of bleeding. Patient 6 had a pericardial tamponade on day 1. Of note, he had been on combination therapy dabigatran plus aspirin. Patient 5 underwent a re-intervention on day 1 for placement on extracorporeal membrane oxygenation support because of primary graft failure, and for a bleeding at the right atrium.
Finally, patient 8 (a re-transplant procedure because of antibody mediated rejection) needed transfusion of 5 units packed cells because of postoperative anaemia, but no re-intervention was needed. Of note, he had received perioperative plasmapheresis because of pre-existing donor specific antibodies. Unfortunately, patient 5 died on day 29 from multiple organ failure and patient 8 died on day 23 from pneumonia. None of those deaths were a direct consequence of bleeding. All other patients are alive at a mean follow-up time of 1.8 years. No adverse reactions or unexpected events that could potentially be related to idarucizumab administration were noted. There were no thrombotic complications.
We compared peroperative transfusion and postoperative bleeding events with non-VAD patients who received a heart transplantation at our centre between August 2013 and July 2018. Patients on VKA (n = 17), reversed with vitamin K and prothrombin complex concentrates, received on average 1.2 units packed cells, 3.5 units fresh frozen plasma, 0.8 pools platelets and 687 mL of recovered blood; four patients (23.5%) needed re-intervention because of bleeding. Patients without preoperative anticoagulation (n = 22) received 1.3 units packed cells, 2.7 units fresh frozen plasma, 0.9 pools platelets and 398 mL of recovered blood; one patient (4.5%) needed re-intervention because of bleeding. Although the small sample size precludes any firm conclusions, none of these differences were statistically significant between the three cohorts (ANOVA for continuous variables, Fisher's exact test for proportions, P > 0.05). Note that two patients (11.8 %) of the VKA group and 12 patients (54.5%) of the non-anticoagulated group were on aspirin.
This is the largest report describing the use of idarucizumab to normalize coagulation in patients on dabigatran awaiting heart transplantation. Most patients presented early after last dabigatran intake (on average 6.2 h). This was reflected by the high dabigatran concentration at baseline (mean 117.8 ng/mL). Administration of 5 g of idarucizumab led to a sustained and complete biochemical reversal, without thrombotic complications, and without interfering with heparinization for cardiopulmonary bypass. However, there still were some bleeding events. Recently, the FDA approved andexanet alfa to reverse anticoagulation in patients treated with factor Xa inhibitors (apixaban and rivaroxaban) who present with life-threatening bleeding. Reversal of factor Xa inhibitors with andexanet prior to urgent surgery has not yet been studied. Importantly, because andexanet alfa also neutralizes heparin, it cannot be used during surgical procedures requiring heparinization.
In conclusion, the availability of an immediately-acting complete reversal agent makes dabigatran an attractive choice for non-VAD patients with non-valvular atrial fibrillation who are listed for heart transplantation. 
